Literature DB >> 22442755

Sub-optimal CD4 T-lymphocyte responses among HIV infected patients who develop TB during the first year of ART.

Ingrid Eshun-Wilson1, Jantjie J Taljaard, Jean B Nachega.   

Abstract

STUDY
BACKGROUND: Poor CD4 T-lymphocyte responses to anti-retroviral treatment (ART) are associated with increased HIV disease progression and mortality. In sub-Saharan Africa a substantial proportion of HIV infected patients are co-infected with TB. This study evaluated the effect of active TB presenting after ART initiation on immunological responses to ART.
METHODS: A retrospective cohort study was conducted of patients initiated on ART in a South African academic hospital between 1 January 2004 and 15 May 2008. Changes in CD4 T-lymphocyte count, virological suppression and incident TB episodes occurring in the first year of ART were assessed. Sub-optimal CD4 responses were defined as 'failure to increase CD4 T-lymphocyte count by 50cells/μl at 6 month on ART'.
RESULTS: The cohort for analysis included 691 patients. 141 (20.4%) had sub-optimal CD4 responses at 6 months on ART. 49 patients (7.1%) developed incident TB within the first 12 months of ART. After adjustment for age, sex, baseline CD4 count and detectable viral load, patients with incident TB were found to have a 2.20 times greater odds of a sub-optimal CD4 response at 6 month of ART as compared to those who were TB free (95%CI: 1.14-4.23).
CONCLUSION: Incident TB was associated with a poor CD4 response during early ART in this cohort. Although the direction of causality cannot be determined from these data, these findings provide additional support for the initiation of ART at higher CD4 counts.

Entities:  

Year:  2012        PMID: 22442755      PMCID: PMC3308912          DOI: 10.4172/2155-6113.1000135

Source DB:  PubMed          Journal:  J AIDS Clin Res


  15 in total

1.  Prognostic factors of combined viral load and CD4+ cell count responses under triple antiretroviral therapy, Aquitaine cohort, 1996-1998.

Authors:  C Marimoutou; G Chêne; P Mercié; D Neau; S Farbos; P Morlat; J Ceccaldi; F Dabis
Journal:  J Acquir Immune Defic Syndr       Date:  2001-06-01       Impact factor: 3.731

2.  Tuberculosis-associated severe CD4+ T-lymphocytopenia in HIV-seronegative patients from Dakar. SIDAK Research Group.

Authors:  S J Kony; A A Hane; B Larouzé; A Samb; S Cissoko; P S Sow; M Sané; M Maynart; G Diouf; J F Murray
Journal:  J Infect       Date:  2000-09       Impact factor: 6.072

3.  Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort.

Authors:  Stephen D Lawn; Motasim Badri; Robin Wood
Journal:  AIDS       Date:  2005-12-02       Impact factor: 4.177

4.  Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy.

Authors:  S Grabar; V Le Moing; C Goujard; C Leport; M D Kazatchkine; D Costagliola; L Weiss
Journal:  Ann Intern Med       Date:  2000-09-19       Impact factor: 25.391

5.  Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control.

Authors:  Stephen D Lawn; Landon Myer; Linda-Gail Bekker; Robin Wood
Journal:  AIDS       Date:  2006-08-01       Impact factor: 4.177

6.  Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa.

Authors:  Sabine M Hermans; Agnes N Kiragga; Petra Schaefer; Andrew Kambugu; Andy I M Hoepelman; Yukari C Manabe
Journal:  PLoS One       Date:  2010-05-07       Impact factor: 3.240

7.  Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration.

Authors:  Suely H Tuboi; Martin W G Brinkhof; Matthias Egger; Roslyn A Stone; Paula Braitstein; Denis Nash; Eduardo Sprinz; François Dabis; Lee H Harrison; Mauro Schechter
Journal:  J Acquir Immune Defic Syndr       Date:  2007-05-01       Impact factor: 3.731

8.  Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.

Authors:  Felipe García; Elisa de Lazzari; Montserrat Plana; Pedro Castro; Gabriel Mestre; Meritxell Nomdedeu; Emilio Fumero; Esteban Martínez; Josep Mallolas; José L Blanco; José M Miró; Tomás Pumarola; Teresa Gallart; José M Gatell
Journal:  J Acquir Immune Defic Syndr       Date:  2004-06-01       Impact factor: 3.731

9.  Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical significance.

Authors:  Damalie Nakanjako; Agnes Kiragga; Fowzia Ibrahim; Barbara Castelnuovo; Moses R Kamya; Philippa J Easterbrook
Journal:  AIDS Res Ther       Date:  2008-10-28       Impact factor: 2.250

10.  CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa.

Authors:  Stephen D Lawn; Landon Myer; Linda-Gail Bekker; Robin Wood
Journal:  BMC Infect Dis       Date:  2006-03-21       Impact factor: 3.090

View more
  6 in total

1.  Construction of Machine Learning Models to Predict Changes in Immune Function Using Clinical Monitoring Indices in HIV/AIDS Patients After 9.9-Years of Antiretroviral Therapy in Yunnan, China.

Authors:  Bingxiang Li; Mingyu Li; Yu Song; Xiaoning Lu; Dajin Liu; Chenglu He; Ruixian Zhang; Xinrui Wan; Renning Zhang; Ming Sun; Yi-Qun Kuang; Ya Li
Journal:  Front Cell Infect Microbiol       Date:  2022-05-12       Impact factor: 6.073

2.  AIDS prevention and control in the Yunnan region by T cell subset assessment.

Authors:  Ya Li; Chenglu He; Zengpin He; Min Zhong; Dajin Liu; Ruiyang Liu; Ruixuan Fan; Yong Duan
Journal:  PLoS One       Date:  2019-04-18       Impact factor: 3.240

3.  Treatment failure and associated factors among first line patients on highly active antiretroviral therapy in Ethiopia: a systematic review and meta-analysis.

Authors:  Moges Agazhe Assemie; Muluneh Alene; Daniel Bekele Ketema; Selishi Mulatu
Journal:  Glob Health Res Policy       Date:  2019-10-30

4.  The effect of tuberculosis on immune reconstitution among HIV patients on highly active antiretroviral therapy in Adigrat general hospital, eastern Tigrai, Ethiopia; 2019: a retrospective follow up study.

Authors:  Hadush Negash; Haftom Legese; Mebrahtu Tefera; Fitsum Mardu; Kebede Tesfay; Senait Gebresilasie; Berhane Fseha; Tsega Kahsay; Aderajew Gebrewahd; Brhane Berhe
Journal:  BMC Immunol       Date:  2019-12-05       Impact factor: 3.615

5.  The impact of tuberculosis co-infection on virological failure among adults living with HIV in Ethiopia: A systematic review and meta-analysis.

Authors:  Temesgen Getaneh; Ayenew Negesse; Getenet Dessie; Melaku Desta
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2022-03-04

6.  The effect of incident tuberculosis on immunological response of HIV patients on highly active anti-retroviral therapy at the university of Gondar hospital, northwest Ethiopia: a retrospective follow-up study.

Authors:  Abate Assefa; Baye Gelaw; Gebeyaw Getnet; Gashaw Yitayew
Journal:  BMC Infect Dis       Date:  2014-08-27       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.